Case Studies in Common Drug-Drug Interactions in People with HIV: A STEP-HIV Initiative
Release Date: November 9, 2021
Support for this activity has been made possible through educational grants from Gilead Sciences and ViiV Healthcare.
Drug-drug interactions between antiretrovirals and other medications are common and may lead to increased or decreased drug levels. In some instances, a change in drug levels may increase the frequency and severity of toxicities or diminish therapeutic responses. When reviewing a patient’s medication profile, performing a medication reconciliation or prescribing medications for a patient, all members of the health care team must consider the potential for drug-drug interactions.
Using a case-based approach, this free interactive CME/CNE-Certified webinar will highlight common drug-drug interactions encountered during the care of patients with HIV and recommend strategies for management.
After participating in the activity, learners should be better able to:
- Identity common drug-drug interactions between antiretrovirals and concomitant medications in patients with HIV infection.
- Recommend appropriate medication changes or adjustments for drug-drug interactions that are common among patients with HIV infection.
- Identify the most reliable resources for drug information related to the management of drug interactions in patients with HIV infection.
|Jason Schafer, PharmD, MPH|
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
|Joseph DeSimone, Jr. MD
Professor of Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Dr. Jason Schafer is a Professor and Vice Chair in the Department of Pharmacy Practice at the Jefferson College of Pharmacy in Philadelphia, Pennsylvania. He also currently practices as an HIV clinical pharmacy specialist in the Division of Infectious Diseases at Thomas Jefferson University.
Dr. Schafer received his Doctor of Pharmacy degree from Duquesne University and completed a pharmacy practice residency at UPMC Mercy Hospital of Pittsburgh and a second residency specializing in infectious diseases at the Ohio State University Wexner Medical Center. He received his Master of Public Health degree from the Jefferson College of Population Health. He is board-certified in pharmacotherapy (BCPS) and infectious diseases (BCIDP) and is credentialed by the American Academy of HIV Medicine as an HIV Pharmacist (AAHIVP).
Dr. Schafer has published numerous peer-reviewed articles, abstracts and book chapters on HIV medicine and infectious diseases pharmacotherapy. These include the Guidelines on Pharmacist Involvement in HIV Care published by the American Society of Health System Pharmacists and endorsed by the American Academy of HIV Medicine and HIV Pharmacotherapy, The Pharmacist’s Role in Care and Treatment.
Dr. DeSimone is a Professor of Medicine and the Associate Program Director for the Infectious Diseases Fellowship Program at Thomas Jefferson University. Dr. DeSimone graduated from Hahnemann School of Medicine in 1994. He has been a part of Jefferson since 1994, having completed both his Internal Medicine residency training and Infectious Diseases fellowship training there. He joined the faculty at Jefferson in 1999, and became the fellowship Program Director in 2003. Dr. DeSimone is responsible for teaching infectious diseases and HIV to medical students, internal medicine residents, and infectious diseases fellows. He has received numerous teaching awards while at Jefferson.
Dr. DeSimone has been providing clinical care at Jefferson for over 20 years. He performs approximately 700 new infectious diseases inpatient consults per year at Thomas Jefferson University Hospital. Dr. DeSimone personally provides care to over 300 HIV-infected patients in the Thomas Jefferson University HIV ambulatory practice. He has acted as the principal or co-principal investigator for dozens of clinical trials investigating antiretroviral therapy for persons with HIV infection. Dr. DeSimone has had numerous publications in peer-reviewed journals and abstract presentations at national meetings.
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and ACTHIV Institute. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Nurses
American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours (0.8 Pharmacotherapeutic Contact Hours).
Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.0 contact hours.
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 5, 2022. PAs should only claim credit commensurate with the extent of their participation.
Other members of the care team will receive a certificate of participation.
This activity has been designed to meet the educational needs of the HIV care team, including physicians (both specialists and primary care/family medicine), nurses, nurse practitioners, physician assistants, and pharmacists who are in practice but are newer to HIV medicine or who are in training. Other healthcare providers may also participate.
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Jason Schafer, PharmD, MPH discloses the following relevant financial relationships: Advisory Board/Consultant: Merck, ViiV Healthcare; Grant/Research Support: Gilead Sciences, Merck
Joseph DeSimone, Jr. MD has no relevant financial relationships to disclose.
John JD Juchniewicz, MCIS, CHCP, FACEHP, Natalie Kirkwood, RN, BSN, JD, American Academy of CME: No relevant financial relationships to disclose.
This activity may contain discussion of off-label or investigational information.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.
Instructions on How to Receive Credit
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CE credit for your participation, please complete the post-assessment and program evaluation. Your certificate will be emailed to you.
This program should be viewed at a resolution of 1024 x 768 or higher using current versions of Microsoft Internet Explorer, Firefox, Chrome or Safari. A high-speed Internet connection is recommended.
© 2021. This CME/CE-certified activity is held as copyrighted © by American Academy of CME and ACTHIV Institute. Through this notice, the Academy and ACTHIV Institute grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).